Quantcast
Last updated on April 16, 2014 at 12:01 EDT

Elk OrthoBiologics To Present At Biotech Showcase(TM) 2013

January 3, 2013

VICTORIA, Australia, Jan. 3, 2013 /PRNewswire/ — Elk OrthoBiologics Limited, an Australian biotechnology company developing a minimally invasive biologic therapy for repairing aseptically loosened hip and knee prosthetic implants, announced today that Andrew Bray, Ph.D., Managing Director and Chief Executive Officer, will present at Biotech Showcase(TM) 2013 being held January 7-9, 2013 in San Francisco, CA. Dr. Bray will discuss the Company’s recent name change from Broadvector Limited to Elk OrthoBiologics Limited, the Company’s new strategic focus, details on its lead program CTL102 using its Gene Directed Enzyme Prodrug Therapy (GDEPT) technology platform for prosthetic joint repair and its plans to commence a Phase 2a program in 2013.

    Details of the presentation are as follows:

            Date:             Tuesday,
                              January 8,
                              2013
              -----          -----------

            Time:             4:45 p.m.
                              PT
              -----          ----------

               Parc 55
                              Wyndham
                              San
                              Francisco-
                              Union
                              Square,
                              Powell
                              Room
            Place:            (Track B)
             ------          -----------

Biotech Showcase(TM) is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences.

About Elk OrthoBiologics Limited
Elk OrthoBiologics, formerly Broadvector Limited, is an Australian-based, public unlisted biotechnology company developing a minimally invasive biologic therapy for repairing aseptically loosened hip and knee prosthetic implants. This unique therapy avoids the need for major surgery and general anesthesia. Elk’s therapy addresses an important and growing unmet medical need.

Elk’s lead program CTL102 is based upon its Gene Directed Enzyme Prodrug Therapy (GDEPT) technology platform. CTL102 recently completed a successful Phase 1 clinical study in elderly patients suffering from debilitating levels of aseptic loosening. The Company expects to commence a Phase 2a study in 2013.

www.elkortho.com

INVESTORS/MEDIA CONTACT
Jenene Thomas
Elk Orthobiologics Limited
Investor Relations and Corporate Communications
Jenene.thomas@elkortho.com
+1(908) 938-1475

SOURCE Elk OrthoBiologics Limited


Source: PR Newswire